|
Constipation
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The presence of CRBN AA (rs6768972) or TT (rs1672753) genotypes was associated with about 333-fold and 250-fold lower risk of constipation in the course of therapy (OR = 0·003; OR = 0·004, respectively).
|
31115923 |
2019 |
|
Hyperbilirubinemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Of the observed SNVs, no associations with KRd therapy response were found in this patient cohort, although strong trends in hypoalbuminemia grade and hyperbilirubinemia grade emerged across the CRBN rs1672753 genotype (P = 0.0008) and the rs1714327 genotype (P = 0.0010), respectively.
|
31619706 |
2019 |
|
Peripheral Neuropathy
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients.
|
31115923 |
2019 |
|
Polyneuropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Selected CRBN SNPs may be useful in assessing the probability of AEs in the form of peripheral polyneuropathy and gastrointestinal motility disorders associated with the use of thalidomide in patients with MM.
|
31115923 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Notably, we found that the ability of cancer migration and invasion was significantly enhanced in CRBN<sup>KO</sup> H1299 and CRBN<sup>KO</sup> MCF7 cancer cells, as compared with those of control cancer cells.
|
31620128 |
2019 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
BI-3663 (cereblon-based) degrades PTK2 with a median DC<sub>50</sub> of 30 nM to >80% across a panel of 11 HCC cell lines.
|
30739444 |
2019 |
|
Peripheral Nervous System Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients.
|
31115923 |
2019 |
|
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
Here we show that thalidomide is not teratogenic in transgenic mice expressing human cereblon, indicating that binding to cereblon is not sufficient to cause birth defects.
|
30190590 |
2018 |
|
Bone Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
However, these processes could be abolished by suppressing AMPK-α with its inhibitor, Compound C. Collectively, our data suggested that CRBN is a potential treatment option against diabetes-induced osteolytic bone disease.
|
29353038 |
2018 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Therapeutically, CRBN engagers have the potential for broad applications in cancer and immune therapy by specifically reducing protein expression through targeted ubiquitin-mediated degradation.
|
29449372 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, our results suggest that aerobic exercise training may provide an important physiological treatment for type 1 diabetes by decreasing CRBN and increasing AMPK signaling in skeletal muscle.
|
29730289 |
2018 |
|
Osteopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
What's more, CRBN ablation suppressed osteoclast differentiation and rescued diabetic bone loss in vivo, accompanied with decreased receptor activator of NF-kB ligand (RANKL), RANKL/osteoprotegerin (OPG), and tartrate-resistant acid phosphatase (TRAP) levels, as well as improved AMP-activated kinase (AMPK) α/acetyl-CoA carboxylase (ACC)αactivation.
|
29353038 |
2018 |
|
Osteoporosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we presented results indicating that CRBN could effectively regulate osteoporosis development.
|
29353038 |
2018 |
|
Septicemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of CRBN in macrophage of KO mice suppressed activation of 5' adenosine monophosphate-activated protein kinase (AMPK) and HO-1 and augmented expression of TNF-α and HMGB1 as inhibition of AMPK by compound C. These studies demonstrate the contribution of CRBN expression to the pathogenesis of CLP-induced sepsis and peritoneal macrophage responses and suggest a novel therapeutic modality for polymicrobial sepsis.
|
29170136 |
2018 |
|
Congenital defects
|
0.010 |
Biomarker
|
group |
BEFREE |
Here we show that thalidomide is not teratogenic in transgenic mice expressing human cereblon, indicating that binding to cereblon is not sufficient to cause birth defects.
|
30190590 |
2018 |
|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, there are no data on CRBN and MUM1 expression in MALT lymphoma.
|
28833354 |
2018 |
|
Sepsis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of CRBN in macrophage of KO mice suppressed activation of 5' adenosine monophosphate-activated protein kinase (AMPK) and HO-1 and augmented expression of TNF-α and HMGB1 as inhibition of AMPK by compound C. These studies demonstrate the contribution of CRBN expression to the pathogenesis of CLP-induced sepsis and peritoneal macrophage responses and suggest a novel therapeutic modality for polymicrobial sepsis.
|
29170136 |
2018 |
|
Gastric lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, a subgroup analysis of gastric lymphoma revealed a significantly better PFS for CRBN- and MUM1- patients, respectively (both P < 0.05).
|
28833354 |
2018 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Our study reveals a novel role of CRBN and the underlying molecular mechanism in the regulation of misfolded proteins in neurodegenerative diseases, which may provide new insights for finding pharmacological targets for these diseases.
|
29272390 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Therapeutically, CRBN engagers have the potential for broad applications in cancer and immune therapy by specifically reducing protein expression through targeted ubiquitin-mediated degradation.
|
29449372 |
2018 |
|
Familial primary gastric lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, there are no data on CRBN and MUM1 expression in MALT lymphoma.
|
28833354 |
2018 |
|
Extranodal marginal zone B-cell lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
|
28833354 |
2018 |
|
Cognition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Although little is known about the function of human cereblon (CRBN), its relationship to mild cognitive deficits suggests that it is involved in the basic processes of human memory and learning.
|
28143899 |
2017 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.010 |
Biomarker
|
disease |
BEFREE |
Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis.
|
28529032 |
2017 |
|
Impaired cognition
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although little is known about the function of human cereblon (CRBN), its relationship to mild cognitive deficits suggests that it is involved in the basic processes of human memory and learning.
|
28143899 |
2017 |